Abstract
Native lung surfactant (LS) consists of a mixture of lipids and proteins that together posses the ability to
lower the alveolar surface tension, and thus is essential for normal breathing. While the exact mechanisms of
acute lung injury (ALI), and its more severe form, acute respiratory distress syndrome (ARDS), are currently
not well understood, LS inactivation by surface active inhibitory proteins, enzymes, fatty acids and lyso-lipids
are believed to play a contributing role. Published and preliminary work reveals that even small fractions of
ARDS-implicated components may change the surface viscosity and elasticity of monolayers by orders of
magnitude: thousand-fold increases in phospholipid monolayer stiffness when saturated fatty acids are added
or albumin adsorbs, whereas 100-1000-fold decreases occur when 1-2% cholesterol is added.
These results suggest a plausible mechanical mechanism for ARDS progression, and the central
hypothesis of the proposed project: that the rheological (e.g. viscous and elastic) properties of ARDS-
inactivated LS play a central, causative role in the ARDS cascade, and in the inability of RS therapies to
effectively reverse ARDS progression. An initial insult to the lung introduces blood proteins through
permeabilized alveolar walls, and heightened levels of the enzyme PLA2, as part of the inflammatory response.
Previous results suggest that either of these situations would create heterogeneous, rheologically elastic
domains deep in the lung: PLA2 by digesting phospholipids to produce lyso-lipids and fatty acids, and blood
proteins through adsorption. Well-known phenomena in continuum mechanics suggest that elastic
heterogeneities within the LS strongly resist the curvature changes that occur naturally during respiration, and
may even `crack' or `crumple' rather than deform smoothly. Such abnormal deformations would thus exert
strong, localized mechanical stresses on the alveolar epithelium, promoting further tissue damage and
inflammation, and ultimately to greater levels of protein and PLA2. Notably, the hypothesized mechanism is
physical in origin, and derives from how the organization of these components in the LS monolayer affects their
ability to flow and deform. Such a mechanism could not be uncovered from chemical assays alone.
To test this hypothesis, the impact of LS-inactivating factors (blood proteins, fatty acids, enzymes) on
the rheology of model LS monolayers will be measured with first-of-their-kind techniques, as well components
(e.g. natural or synthetic surfactant proteins, mono-unsaturated fatty acids, cholesterol) that may reduce or
reverse the inactivation. Using both novel experimental techniques and theory, the molecular composition of
inactivated LS will be related to elastic heterogeneities, and elastic heterogeneities to anisotropic alveolar
inflation and deflation. Finally, the mixing and evolution of heterogeneous monolayers will be studied to
identify strategies to dissolve, disrupt or displace these elastic heterogeneities, and ultimately guiding
therapeutic formulations.
